RCS - Spexis AG - CARB-X milestone

Spexis AG

03/03/2022 07:08

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220303:nRSC5101Da&default-theme=true

RNS Number : 5101D  Spexis AG  03 March 2022

 Spexis AG / Key word(s): Agreement/Financing

Spexis achieves first CARB-X milestone for its thanatin derivatives program
 and receives funding of up to USD 1.9 million to initiate lead optimization

03-March-2022

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.

 Ad hoc announcement pursuant to Art. 53 LR

 Allschwil, Switzerland, March 03(rd) 2022

Spexis achieves first CARB-X milestone for its thanatin derivatives program
 and receives funding of up to USD 1.9 million to initiate lead optimization

 Spexis AG (SIX: SPEX) announced today that it has been awarded the second part
 of its phased funding grant from CARB-X (Combating Antibiotic-Resistant
 Bacteria Biopharmaceutical Accelerator), the global partnership led by Boston
 University dedicated to supporting the development of antibacterial products
 to diagnose, prevent and treat drug-resistant infections. Spexis has received
 this award based upon the achievement of technical milestones within the
 previously announced CARB-X collaboration for this program. The award will
 support the continuation of the "thanatin derivatives program" belonging to
 Spexis' novel Outer Membrane Protein Targeting Antibiotic (OMPTA) class of
 antibiotics to potentially treat life-threatening infections caused by
 difficult-to-treat Gram-negative bacteria.

 CARB-X has committed to provide Spexis with initial funding of up to USD 1.9
 million to initiate lead optimization. Spexis will be eligible for a potential
 of up to USD 8.84 million in additional funds to nominate the preclinical
 candidate if project milestones are met, pending certain conditions.

 "We are very pleased to have met the program objectives required to receive
 this important milestone grant, which allows us to take this program to the
 next phase of development together with our colleagues at CARB-X. This program
 targets Enterobacteriaceae, one of the most common families of
 life-threatening Gram-negative pathogens, including extremely drug resistant
 strains, and which are among the WHO priority-1 pathogens," said Jeff Wager,
 M.D., Chief Executive Officer of Spexis. "This award will ensure timely
 continuation of this important program, and we are grateful to CARB-X for
 their ongoing support and partnership."

 The thanatin-derivative antibiotics discovered by Spexis and the University of
 Zurich are part of Spexis' new Outer Membrane Protein Targeting Antibiotic
 (OMPTA) class of antibiotics and target the lipopolysaccharide (LPS) transport
 protein A (LptA), a novel essential target in the LPS transport mechanism of
 Gram-negative bacteria.

 For further information please contact:

For Investors:                               For Media:

Hernan Levett
 Dr. Stephan Feldhaus

Chief Financial Officer
 Feldhaus & Partner

Spexis AG.
 +41 79 865 92 56

+41 61 567 16 00                            feldhaus@feldhaus-partner.ch (mailto:feldhaus@feldhaus-partner.ch)
 IR@spexisbio.com (mailto:IR@spexisbio.com)

 

 About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
 Switzerland focused on rare diseases and oncology. The current pipeline of the
 company is a combination of two legacy companies, Polyphor and EnBiotix, which
 merged in December 2021. The combined company has been renamed to Spexis AG
 and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For
 further information please visit: www.spexisbio.com
 (http://www.spexisbio.com/) .

 About CARB-X
 CARB-X (https://carb-x.org/) (Combating Antibiotic-Resistant Bacteria
 Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to
 supporting early development antibacterial R&D to address the rising
 threat of drug-resistant bacteria. CARB-X is led by Boston University and
 funding is provided by the Biomedical Advanced Research and Development
 Authority (https://www.phe.gov/about/BARDA/Pages/default.aspx) (BARDA), part
 of the Office of the Assistant Secretary for Preparedness and Response (ASPR)
 in the US Department of Health and Human Services; the Wellcome Trust
 (https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections) , a
 global charity based in the UK working to improve health globally; Germany's
 Federal Ministry of Education and Research (BMBF)
 (https://fundit.fr/en/institutions/german-federal-ministry-education-and-research-bmbf)
 ; the UK Department of Health and Social Care's Global Antimicrobial
 Resistance Innovation Fund (GAMRIF)
 (https://www.gov.uk/government/groups/the-global-amr-innovation-fund) funded
 by the UK Government Department of Health and Social Care (DHSC)
 (https://www.gov.uk/government/organisations/department-of-health-and-social-care)
 ; the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) ,
 and with in-kind support from National Institute of Allergy and Infectious
 Diseases (https://www.niaid.nih.gov/) (NIAID), part of the US National
 Institutes of Health (NIH) within the US Department of Health and Human
 Services. CARB-X is investing up to US$480 million from 2016-2022 to support
 innovative therapeutics, preventatives and rapid diagnostics. CARB-X funds
 only projects that target drug-resistant bacteria highlighted on the CDC's
 Antibiotic Resistant Threats list
 (https://www.cdc.gov/drugresistance/biggest_threats.html) , or the Priority
 Bacterial Pathogens list published by the WHO,
 (http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/)
 with a priority on those pathogens deemed Serious or Urgent on the CDC list
 (https://www.cdc.gov/drugresistance/biggest-threats.html) or Critical or High
 on the WHO list
 (https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf)
 . CARB-X is headquartered at Boston University School of Law
 (http://www.bu.edu/law/) . https://carb-x.org/ (https://carb-x.org/) . Follow
 us on Twitter @CARB_X.

 Disclaimer

This press release contains forward-looking statements which are based on
 current assumptions and forecasts of Spexis management. Known and unknown
 risks, uncertainties, and other factors could lead to material differences
 between the forward-looking statements made here and the actual development,
 in particular Spexis' results, financial situation, and performance. Readers
 are cautioned not to put undue reliance on forward-looking statements, which
 speak only of the date of this communication. Spexis disclaims any intention
 or obligation to update and revise any forward-looking statements, whether as
 a result of new information, future events or otherwise.

This research is supported by CARB-X. CARB-X funding for this research is
 supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and
 by awards from Wellcome Trust and Germany's Federal Ministry of Education and
 Research (BMBF). The contents are solely the responsibility of the authors and
 do not necessarily represent the official views of CARB-X or any of its
 funders.

 Additional features:

File: Spexis achieves first CARB-X milestone for its thanatin derivatives
 program
 (https://eqs-cockpit.com/c/fncls.ssp?u=e9c239936b38e648f7558a39cd261d68)

 End of ad hoc announcement

 

About Spexis

Spexis is a clinical-stage biopharmaceutical company based in Allschwil,
Switzerland focused on rare diseases and oncology. The current pipeline of the
company is a combination of two legacy companies, Polyphor and EnBiotix, which
merged in December 2021. The combined company has been renamed to Spexis AG
and is trading on the SIX Swiss Exchange under the symbol SIX:SPEX. For
further information please visit: www.spexisbio.com
(http://www.spexisbio.com/) .

About CARB-X
CARB-X (https://carb-x.org/) (Combating Antibiotic-Resistant Bacteria
Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to
supporting early development antibacterial R&D to address the rising
threat of drug-resistant bacteria. CARB-X is led by Boston University and
funding is provided by the Biomedical Advanced Research and Development
Authority (https://www.phe.gov/about/BARDA/Pages/default.aspx) (BARDA), part
of the Office of the Assistant Secretary for Preparedness and Response (ASPR)
in the US Department of Health and Human Services; the Wellcome Trust
(https://wellcome.ac.uk/what-we-do/our-work/drug-resistant-infections) , a
global charity based in the UK working to improve health globally; Germany's
Federal Ministry of Education and Research (BMBF)
(https://fundit.fr/en/institutions/german-federal-ministry-education-and-research-bmbf)
; the UK Department of Health and Social Care's Global Antimicrobial
Resistance Innovation Fund (GAMRIF)
(https://www.gov.uk/government/groups/the-global-amr-innovation-fund) funded
by the UK Government Department of Health and Social Care (DHSC)
(https://www.gov.uk/government/organisations/department-of-health-and-social-care)
; the Bill & Melinda Gates Foundation (https://www.gatesfoundation.org/) ,
and with in-kind support from National Institute of Allergy and Infectious
Diseases (https://www.niaid.nih.gov/) (NIAID), part of the US National
Institutes of Health (NIH) within the US Department of Health and Human
Services. CARB-X is investing up to US$480 million from 2016-2022 to support
innovative therapeutics, preventatives and rapid diagnostics. CARB-X funds
only projects that target drug-resistant bacteria highlighted on the CDC's
Antibiotic Resistant Threats list
(https://www.cdc.gov/drugresistance/biggest_threats.html) , or the Priority
Bacterial Pathogens list published by the WHO,
(http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/)
with a priority on those pathogens deemed Serious or Urgent on the CDC list
(https://www.cdc.gov/drugresistance/biggest-threats.html) or Critical or High
on the WHO list
(https://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf)
. CARB-X is headquartered at Boston University School of Law
(http://www.bu.edu/law/) . https://carb-x.org/ (https://carb-x.org/) . Follow
us on Twitter @CARB_X.

Disclaimer

This press release contains forward-looking statements which are based on
current assumptions and forecasts of Spexis management. Known and unknown
risks, uncertainties, and other factors could lead to material differences
between the forward-looking statements made here and the actual development,
in particular Spexis' results, financial situation, and performance. Readers
are cautioned not to put undue reliance on forward-looking statements, which
speak only of the date of this communication. Spexis disclaims any intention
or obligation to update and revise any forward-looking statements, whether as
a result of new information, future events or otherwise.

This research is supported by CARB-X. CARB-X funding for this research is
supported by the Cooperative Agreement Number IDSEP160030 from ASPR/BARDA and
by awards from Wellcome Trust and Germany's Federal Ministry of Education and
Research (BMBF). The contents are solely the responsibility of the authors and
do not necessarily represent the official views of CARB-X or any of its
funders.

 

Additional features:

File: Spexis achieves first CARB-X milestone for its thanatin derivatives
program
(https://eqs-cockpit.com/c/fncls.ssp?u=e9c239936b38e648f7558a39cd261d68)

 

End of ad hoc announcement

 

 Language:     English
 Company:      Spexis AG
               Hegenheimermattweg 125
               4123 Allschwil
               Switzerland
 Phone:        +41 61 567 1600
 Fax:          +41 61 567 1601
 E-mail:       info@spexisbio.com
 Internet:     www.spexisbio.com
 ISIN:         CH0106213793
 Valor:        SPEX
 Listed:       SIX Swiss Exchange
 EQS News ID:  1293143

 

 End of Announcement  EQS News Service

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAQXLBBLXLXBBZ